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Abstract
Background: We present the clinical course of a pediatric patient with large rhabdomyosarcoma of the body trunk
who received proton beam therapy (PBT).
Case presentation: A 1-year-old girl was diagnosed with stage IV alveolar rhabdomyosarcoma in 2008. A large
tumor was located in the central diaphragm and had infiltrated the liver and pericardium with peritoneal
dissemination. Chemotherapy was immediately started with six courses of vincristine, actinomycin-D and
cyclophosphamide (VAC) firstly, and secondly followed by 2 courses of ifosfamide, carboplatin and etoposide (ICE),
but a large tumor of 15 cm in size remained. The tumor was inoperable because of its location, and photon
radiotherapy could not be performed due to limited liver tolerance. The patient was referred to our hospital and
received PBT at a dose of 54 GyE in 30 fractions in June 2009.
The tumor quickly responded and 95 % of volume reduction was achieved at the end of PBT. However, marginal
recurrence in the caudal part of the irradiated field, where we reduced the proton dose because of the presence of
the intestine, was detected in August 2010. The recurrent tumor size was less than 1 cm. Chemotherapy with VAC
followed by topotecan and carboplatin (TC) was again tried, but the tumor size was stable. Repeated PBT was not
possible because of limited intestinal tolerance; therefore, intraoperative radiotherapy was conducted with 20 Gy of
electron beams in April 2011. The tumor was subsequently well controlled, but secondary myelodysplastic
syndrome developed and the patient died of hemophagocytic syndrome after umbilical cord blood transplantation
in May 2012.
Conclusion: PBT was performed safely and effectively for a 1-year-old girl with alveolar rhabdomyosarcoma with
liver and cardiac invasion that was resistant to surgery and chemotherapy. This case illustrates that PBT can be
useful in cases that are difficult to treat with conventional radiotherapy.
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Background
Radiotherapy plays an important role in treatment of
rhabdomyosarcoma (RMS), with a dose of 40–60 Gy
typically required, and hyperfractionation (1.1-Gy twice
daily fractions) or standard fractionation (1.8-Gy daily
fractions) is used for definitive treatment [1]. The risk of
morbidity radiation-related should be carefully considered
depending on the volume and the dose delivered in the
pediatric patients. We experienced a pediatric patient
with an unresectable large alveolar RMS with liver inva-
sion. Photon radiotherapy was considered as the first
treatment choice, but was not administered because of
the lack of tolerance of the liver. Proton beam therapy
(PBT) was chosen in this case, since PBT is a particle
radiotherapy with excellent dose localization because of
the sharp and narrow Bragg peak [2, 3]. Here, we
present the clinical course of the patient after treatment
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Case presentation
A girl aged 1 year and 6 months initially presented with
an abdominal mass with a maximum diameter of over
15 cm. The mass was located in the central diaphragm
and was infiltrating the liver and pericardium with peri-
toneal dissemination. Ascites cytology showed class V in
Papanicolaou’s classification. The patient was diagnosed
as alveolar RMS IRS Stage 4, postoperative group IV,
and classified in the high risk group. Chemotherapy was
started, but the tumor did not shrink sufficiently: with
disease progression after the first 2 courses of VAC every
3 weeks, including vincristine (VCR) + actinomycin-D
(Act-D) + cyclophosphamide (CPA); and partial response
(PR) after 2 courses of ICE, including ifosfamide (IFM)
+ carboplatin (CBDCA) + etoposide (VP-16). Surgical re-
section was not possible for broad tumor’s invasion of
the surrounding diaphragm and radical photon radio-
therapy could not be performed because the liver could
not tolerate the definitive treatment dose. Palliative care
was initially recommended from local pediatric oncolo-
gists, but subsequently the patient and her family visited
our hospital to receive PBT, which was started in June
2009 at age 1 year and 11 months. Peritoneal dissemin-
ation disappeared after the chemotherapy, but the tumor
was still located in the central diaphragm with infiltra-
tion of the liver and pericardium, and the maximum
diameter was still over 8 cm at the point (Fig. 1). One
month after the last chemotherapy (ICE), a PBT dose of
54 GyE in 30 fractions was applied over a course of
58 days. The relative biological effectiveness (RBE) of the
PBT was assumed to be 1.1. We used the passive scatter-
ing method for PBT [4]. During PBT, the patient was
sedated with anesthesia and immobilized in a body cast.
We used a laser displacement sensor (LDS: KEYENCE
LB-300) that was the prototype of AZ-733. Respiratory
gating in the expiratory phase was used. A respiratory
waveform is obtained using a laser range finder that
monitors movement of the abdominal surface, and a
gating signal is developed. The phase shifts between the
respiratory waveform and the 3D tumor motion are
principally in the range 0.0 to 0.3 s, regardless of the
organ being measured in the system [18]. The gating sig-
nal is applied to the accelerator, and the accelerator is
triggered within 0.1 s and delivers proton beams. The
CTV encompassed the gross tumor volume with a 5- to
10-mm margin in all directions. An additional 5-mm
margin was included on the caudal axes to compensate
for uncertainty due to respiration-induced hepatic move-
ments. An additional margin of 10 mm was added to
cover the entire CTV by enlarging the multileaf collima-
tor and adjusting the range shifter. Proton beams from
155 to 250 MeV generated through a linear accelerator
and synchrotron were spread out and shaped with ridge
filters, double-scattering sheets, multicollimators, and a
custom-made bolus to ensure that the beams conformed
to the treatment planning data. The tumor shrunk dur-
ing PBT, and the treatment field was reduced to fit the
tumor size and to keep the intestinal dose within the
50Gy tolerance level [11] (Fig. 2). The tumor showed a
good PR (−95 % of the tumor volume) after PBT and the
acute toxicity was only Grade 1 radiation hepatitis
and dermatitis. After PBT, high dose chemotherapy
with VP-16 + CPA + pirarubicine (THP-ADR) + cisplatin
(CDDP) + VCR, IFM+VP-16 + Act-D + VCR, and irinote-
can (CPT-11) + VCR was continued. The tumor was well
controlled for 1 year with regular follow-up MR or CT
scans performed every 3 months, but then recurred at the
edge of the irradiation field where the irradiation dose was
reduced due to the proximity to the intestine (Fig. 3). The
chemotherapy regimen was changed to low dose VAC, but
the tumor volume remained stable. Repeated radiotherapy
was considered, but could not be administered due to
intestinal tolerance. Therefore, tumor excision with
intraoperative radiotherapy (IORT) using an electron
beam of 20 Gy was conducted in May 2011, at age
3 years and 10 months. After IORT, the tumor was
well controlled and a CT image showed only radi-
ation hepatitis without a tumor (Fig. 4). However, the
patient developed secondary myelodysplastic syndrome
(MDS) in December 2011, and died of hemophagocytic
syndrome after umbilical cord blood transplantation in
May 2012.
Fig. 1 CT images after 6 courses of VAC and 2 courses of ICE, just before the start of PBT
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Discussion
The incidence of soft tissue sarcomas in children and
adolescents younger than 20 years of age is 11.0 per mil-
lion, representing 7.4 % of cancer cases for this age
group [5]. Rhabdomyosarcoma is the most common soft
tissue sarcoma in children aged 0–14 years, representing
nearly 50 % of soft tissue sarcomas for this age range,
with an incidence rate of 4.6 per million. There are two
major types of rhabdomyosarcoma: the embryonal one
which occur in 75 % of the cases and alveolar [6]. The
incidence of embryonal rhabdomyosarcoma is higher
among children aged 0–4 years, while the alveolar
subtype incidence is similar throughout childhood [5].
The embryonal type has a better prognosis than the
alveolar type [7]. The standard therapy for pediatric
rhabdomyosarcoma is multiagent chemotherapy and
local therapy of surgery with or without radiotherapy.
Only 15 % of patients with completely resected embryonal
rhabdomyosarcoma have a good outcome without radio-
therapy, and thus radiotherapy is used in most cases. The
radiotherapy dose mainly depends on the amount of
residual disease, if any, after primary surgical resection,
with doses increased from 36 to 50.4 Gy as the risk in-
creases [8–10]. In our case, the tumor widely involved the
liver, and this prevented definitive radiotherapy because of
the low tolerance of radiation doses of 30, 35, and 50 Gy
for the total, two-thirds, and one-third of the liver, re-
spectively [11]. For comparison, we planned intensity-
modulated radiation therapy (IMRT) using the same
conditions as those used for PBT. In the IMRT plan, the
Fig. 2 The tumor shrunk during PBT and the treatment field was reduced to fit the tumor size. The white line was clinical target volume. The
surrounding low dosing area (arrows) showed acute radiation hepatitis
Fig. 3 These images were contrast enhanced CT image a and PET-CT image b, at 1 year after PBT. In figure a, local recurrence of the tumor is
enhanced at the edge of irradiation, and FDG accumulated same place
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liver volume irradiated with ≥20 Gy (V20) was 60 % at a
treatment dose of 54 Gy, compared to 34 % in PBT. PBT
reduced low dose area and was expected [Fig. 5]. The total
liver volume was 500 cc and the remnant volume was only
200 cc, which made it difficult to administer photon radio-
therapy in the present case. Surgery was also not possible
for broad tumor’s invasion of the surrounding diaphragm
and chemotherapy alone was ineffective. Palliative irradi-
ation was also recommended, but survival was estimated
to be less than one year with palliative therapy. Proton
beams have a Bragg peak in which the dose rapidly falls
off at the end of the beam range at a depth within the
patient. For this reason PBT can deliver a high dose to the
limited volume of a liver tumor while non-cancerous liver
tissue is only exposed to very low doses. PBT also allows
preservation of a larger volume of normal liver tissue
compared to photon radiotherapy. Based on these
advantages, we have treated many patients with liver ma-
lignancies [12–14]. Therefore, we thought that PBT was
reasonable and might be effective in the present case, even
though we had not previously used this approach for
pediatric RMS widely located in the liver. Several reports
have described the advantages of PBT compared to pho-
ton radiotherapy, including IMRT. Cotter et al. found that
proton beams can reduce the dose to normal organs adja-
cent to the tumor, such as the bladder, testis and bones,
compared to IMRT in radiotherapy for bladder or prostate
rhabdomyosarcoma [15]. In spot-scan PBT for pediatric
malignant soft tissue tumor including rhabdomyosarcoma,
Timmerman et al. found high tolerability of PBT and sug-
gested that IMRT requires a wider field compared to PBT;
therefore, PBT results in lower doses to the volume
around the target and the secondary cancer risk is de-
creased [16]. In a phase II study comparing PBT and
IMRT, Ladra et al. reported favorable disease control and
dose distribution [17]. The tumor recurrence 1 year after
PBT in our case may have been due to field shrinkage to
reduce the dose to the gastrointestinal tract after 41.4 GyE.
In adults, a dose of about 50 GyE may be acceptable, but
radiation sensitivity is higher in pediatric patients and may
have been further enhanced by concurrent chemotherapy
in the present case. For these reasons, we reduced the
small bowel dose after administration of 41.4 GyE. The re-
currence was well controlled by IORT. Unfortunately, the
patient died of a regimen-related toxicity of unrelated
cord blood transplantation during treatment for sec-
ondary MDS. However, PBT seemed to be effective
with a good tolerance to the radiation treatment and
with few acute side effects (G1 hepatitis), and potentially
beneficial with IORT to improve the local control. In
conclusion, we suggest that PBT could be a valide and safe
alternative technique to be considered for pediatric pa-
tients with RMS who cannot receive definitive photon
radiotherapy.
Fig. 4 The tumor was well controlled on CT images at 2 months
after IORT
Fig. 5 These graphs showed DVHs of PBT and IMRT for OARs of heart (a), total-lung (b), and liver (c). PBT reduced low-dose area compared with IMRT
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Conclusion
In this case, PBT was performed safely and effectively
with alveolar rhabdomyosarcoma with liver and cardiac
invasion that was unable to be removed with surgery
and was resistant to chemotherapy. We supposed that
side effect and tumor’s local control turned worse, if we
used conventional radiotherapy not PBT. This case illus-
trates that PBT can be useful in cases that are difficult to
treat with conventional radiotherapy.
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